



Sample Information

Patient Name: 許爵禧  
Gender: Male  
ID No.: R103088789  
History No.: 20367786  
Age: 67  
  
Ordering Doctor: DOC8170B 陳亭如  
Ordering REQ.: OCCWLCG  
Signing in Date: 2022/11/23

Path No.: M111-00022  
MP No.: F22130  
Assay: Oncomine Focus Assay  
Sample Type: FFPE  
Block No.: S111-71693A  
Percentage of tumor cells: 20%

Reporting Doctor: DOC5466K 葉奕成 (Phone: 8#5466)

Note:

Sample Cancer Type: Non-Small Cell Lung Cancer

Table of Contents	Page	Report Highlights
Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)	2	1 Relevant Biomarkers
Biomarker Descriptions	2	6 Therapies Available
Relevant Therapy Summary	3	5 Clinical Trials
Relevant Therapy Details	3	
Clinical Trials Summary	15	
Alert Details	15	

Relevant Non-Small Cell Lung Cancer Variants

Gene	Finding	Gene	Finding
ALK	<b>EML4-ALK fusion</b>	NTRK1	None detected
BRAF	None detected	NTRK2	None detected
EGFR	None detected	NTRK3	None detected
ERBB2	None detected	RET	None detected
KRAS	None detected	ROS1	None detected
MET	None detected		

## Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IA	<b>EML4-ALK fusion</b> EMAP like 4 - ALK receptor tyrosine kinase	<b>alectinib</b> <sup>1,2</sup> <b>brigatinib</b> <sup>1,2</sup> <b>ceritinib</b> <sup>1,2</sup> <b>crizotinib</b> <sup>1,2</sup> <b>lorlatinib</b> <sup>1,2</sup> next-generation ALK inhibitor	<b>crizotinib</b> <sup>1</sup> brigatinib ceritinib lorlatinib	5

Public data sources included in relevant therapies: FDA<sup>1</sup>, NCCN, EMA<sup>2</sup>, ESMO

**Tier Reference:** Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

## Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

### DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
BRAF	p.(G474E)	c.1421G>A	.	chr7:140481387	5.55%	NM_004333.6	missense	2000
FGFR1	p.(T726=)	c.2178T>G	.	chr8:38271771	5.32%	NM_001174067.1	synonymous	959
MAP2K1	p.(K64R)	c.191A>G	.	chr15:66727475	4.30%	NM_002755.4	missense	2000
MAP2K1	p.(G210=)	c.630G>T	.	chr15:66774154	4.90%	NM_002755.4	synonymous	2000

### Gene Fusions (RNA)

Genes	Variant ID	Locus	Read Count
EML4-ALK	EML4-ALK.E18A20.COSF487.1	chr2:42543190 - chr2:29446394	60626

## Biomarker Descriptions

### ALK (ALK receptor tyrosine kinase)

**Background:** The ALK gene encodes the ALK receptor tyrosine kinase (RTK) with sequence similarity to the insulin receptor subfamily of kinases<sup>1</sup>. ALK is the target of recurrent alterations in cancer, the most common being chromosomal rearrangements that generate fusion genes containing the intact ALK tyrosine kinase domain combined with multiple partner genes<sup>2</sup>. ALK fusion kinases are constitutively activated and drive oncogenic transformation via activation of downstream STAT3, PI3K/AKT/MTOR, and RAS/RAF/MEK/ERK pathways<sup>2,3,4,5</sup>.

**Alterations and prevalence:** ALK was discovered by positional cloning of translocations involving nucleophosmin (NPM) on 5q35 with a previously unidentified RTK on 2p23 (ALK), which occur in over 50% of anaplastic large cell lymphoma cases (ALCL)<sup>1,6</sup>. In contrast, about 5% of non-small cell lung cancer (NSCLC) cases generate recurrent ALK fusions with EML4, KIF5B, and HIP1<sup>7,8,9</sup>.

**Potential relevance:** The first generation small molecule tyrosine kinase inhibitor (TKI), crizotinib<sup>10</sup>, was FDA approved (2011) for the treatment of ALK positive advanced NSCLC as well as ALK positive ALCL or inflammatory myofibroblastic tumor (IMT). Kinase domain mutations including L1196M, G1269A, F1174L, G1202R, as well as other variants have been shown to confer acquired resistance to crizotinib in ALK positive NSCLC<sup>11,12,13,14</sup>. Other mechanisms of acquired resistance involve amplification of the ALK fusion gene and activation of alternate or bypass signaling pathways involving EGFR, KIT, MET, and IGF1R<sup>15</sup>. In order to overcome acquired resistance, second and third-generation ALK inhibitors including ceritinib<sup>16</sup> (2014), alectinib<sup>17</sup> (2015), brigatinib<sup>18</sup> (2017), and lorlatinib<sup>19</sup> (2018) were developed and approved by the FDA. Two phase III trials evaluating crizotinib and alectinib as first line therapy in NSCLC, including patients with asymptomatic central nervous system (CNS) disease, were conducted and both studies showed consistent higher objective response rates (ORR) with alectinib relative to crizotinib<sup>20,21</sup>. For this reason, alectinib is a preferred first-line treatment of ALK positive NSCLC<sup>22</sup>.

## Relevant Therapy Summary

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

### EML4-ALK fusion

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
crizotinib	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	×
ceritinib	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/> (IV)
lorlatinib	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/> (IV)
brigatinib	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	×
alectinib	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	<input checked="" type="radio"/>	×
next-generation ALK inhibitor	×	×	×	<input checked="" type="radio"/>	×
brigatinib, alectinib	×	×	×	×	<input checked="" type="radio"/> (III)
repotrectinib	×	×	×	×	<input checked="" type="radio"/> (I/II)

\* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

## Relevant Therapy Details

### Current FDA Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

FDA information is current as of 2022-10-19. For the most up-to-date information, search [www.fda.gov](https://www.fda.gov).

### EML4-ALK fusion

#### ☒ crizotinib

**Cancer type:** Inflammatory Myofibroblastic Tumor, Non-Small Cell Lung Cancer

**Label as of:** 2022-07-14

**Variant class:** ALK fusion

#### Indications and usage:

XALKORI® is a kinase inhibitor indicated for the treatment of

- patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.
- pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
  - Limitations of Use: The safety and efficacy of XALKORI® have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.
- adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.

#### Reference:

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/202570s033lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf)

## EML4-ALK fusion (continued)

### ● alectinib

**Cancer type:** Non-Small Cell Lung Cancer

**Label as of:** 2021-09-03

**Variant class:** ALK fusion or ALK overexpression

**Indications and usage:**

ALECENSA® is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

**Reference:**

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/208434s012lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf)

### ● brigatinib

**Cancer type:** Non-Small Cell Lung Cancer

**Label as of:** 2022-02-28

**Variant class:** ALK fusion

**Indications and usage:**

ALUNBRIG® is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

**Reference:**

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/208772s013lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf)

### ● ceritinib

**Cancer type:** Non-Small Cell Lung Cancer

**Label as of:** 2021-10-07

**Variant class:** ALK fusion or ALK overexpression

**Indications and usage:**

ZYKADIA® is a kinase inhibitor indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

**Reference:**

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/211225s004lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf)

### ● lorlatinib

**Cancer type:** Non-Small Cell Lung Cancer

**Label as of:** 2021-03-03

**Variant class:** ALK fusion or ALK overexpression

**Indications and usage:**

LORBRENA® is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

**Reference:**

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/210868s004lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf)

## Current NCCN Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

NCCN information is current as of 2022-10-03. For the most up-to-date information, search [www.nccn.org](http://www.nccn.org).  
For NCCN International Adaptations & Translations, search [www.nccn.org/global/international\\_adaptations.aspx](http://www.nccn.org/global/international_adaptations.aspx).

### EML4-ALK fusion

#### ● alectinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 1

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (First-line therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

#### ● brigatinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 1

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (First-line therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

#### ● ceritinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 1

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (First-line therapy); Other recommended intervention

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

#### ● crizotinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 1

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (First-line therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

## EML4-ALK fusion (continued)

### ● lorlatinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 1

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (First-line therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

### ● alectinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion or ALK overexpression

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Brain Metastases (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 2.2022]

### ● alectinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Metastatic, Advanced (Subsequent therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

### ● brigatinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Brain Metastases (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 2.2022]

## EML4-ALK fusion (continued)

### ● brigatinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Metastatic, Advanced (Subsequent therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

### ● ceritinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Brain Metastases (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 2.2022]

### ● ceritinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

### ● crizotinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

### ● lorlatinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion or ALK overexpression

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Brain Metastases (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 2.2022]

## EML4-ALK fusion (continued)

### ● lorlatinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Metastatic, Advanced (Subsequent therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

### ● crizotinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Brain Metastases (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 2.2022]

### ○ brigatinib

Cancer type: Inflammatory Myofibroblastic Tumor Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Line of therapy not specified); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2022]

### ○ ceritinib

Cancer type: Inflammatory Myofibroblastic Tumor Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Line of therapy not specified); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2022]

### ○ crizotinib

Cancer type: Inflammatory Myofibroblastic Tumor Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Line of therapy not specified); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2022]



## EML4-ALK fusion (continued)

### ○ lorlatinib

Cancer type: Inflammatory Myofibroblastic Tumor Variant class: ALK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Line of therapy not specified); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2022]

## Current EMA Information

☒ In this cancer type    ☐ In other cancer type    ☒ In this cancer type and other cancer types

EMA information is current as of 2022-10-19. For the most up-to-date information, search [www.ema.europa.eu/ema](https://www.ema.europa.eu/ema).

### EML4-ALK fusion

#### ☒ alectinib

Cancer type: Non-Small Cell Lung Cancer

Label as of: 2022-08-11

Variant class: ALK fusion or ALK overexpression

Reference:

[https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf)

#### ☒ brigatinib

Cancer type: Non-Small Cell Lung Cancer

Label as of: 2022-05-18

Variant class: ALK fusion

Reference:

[https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf)

#### ☒ crizotinib

Cancer type: Non-Small Cell Lung Cancer

Label as of: 2022-06-27

Variant class: ALK fusion

Reference:

[https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf)

#### ☒ ceritinib

Cancer type: Non-Small Cell Lung Cancer

Label as of: 2022-02-25

Variant class: ALK positive

Reference:

[https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf)

#### ☒ lorlatinib

Cancer type: Non-Small Cell Lung Cancer

Label as of: 2022-04-07

Variant class: ALK positive

Reference:

[https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf)

## Current ESMO Information

- ☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

ESMO information is current as of 2022-10-03. For the most up-to-date information, search [www.esmo.org](http://www.esmo.org).

### EML4-ALK fusion

#### ● alectinib

**Cancer type:** Non-Small Cell Lung Cancer

**Variant class:** ALK fusion

**ESMO Level of Evidence/Grade of Recommendation:** I / A

**Population segment (Line of therapy):**

- Stage IV (First-line therapy); ESMO-MCBS v1.1 score: 4
- Advanced, Progression (Second-line therapy, Subsequent therapy); ESMO-MCBS v1.1 score: 4

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

#### ● brigatinib

**Cancer type:** Non-Small Cell Lung Cancer

**Variant class:** ALK fusion

**ESMO Level of Evidence/Grade of Recommendation:** I / A

**Population segment (Line of therapy):**

- Stage IV (First-line therapy)

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

#### ● ceritinib

**Cancer type:** Non-Small Cell Lung Cancer

**Variant class:** ALK fusion

**ESMO Level of Evidence/Grade of Recommendation:** I / A

**Population segment (Line of therapy):**

- Advanced, Progression (Second-line therapy, Subsequent therapy); ESMO-MCBS v1.1 score: 4

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

## EML4-ALK fusion (continued)

### ● crizotinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):

- Stage IV (First-line therapy); ESMO-MCBS v1.1 score: 4
- (Second-line therapy, Subsequent therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

### ● next-generation ALK inhibitor

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

ESMO Level of Evidence/Grade of Recommendation: I / A

Population segment (Line of therapy):

- Advanced (Second-line therapy, Subsequent therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

### ● ceritinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

ESMO Level of Evidence/Grade of Recommendation: I / B

Population segment (Line of therapy):

- Stage IV (First-line therapy); ESMO-MCBS v1.1 score: 4

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

### ● crizotinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

ESMO Level of Evidence/Grade of Recommendation: I / B

Population segment (Line of therapy):

- Stage IV (First-line therapy); ESMO-MCBS v1.1 score: 4

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

## EML4-ALK fusion (continued)

### ● next-generation ALK inhibitor

**Cancer type:** Non-Small Cell Lung Cancer

**Variant class:** ALK fusion

**ESMO Level of Evidence/Grade of Recommendation:** II / A

**Population segment (Line of therapy):**

- Advanced, Progression (Second-line therapy, Subsequent therapy)

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

### ● alectinib

**Cancer type:** Non-Small Cell Lung Cancer

**Variant class:** ALK fusion

**ESMO Level of Evidence/Grade of Recommendation:** III / A

**Population segment (Line of therapy):**

- (First-line therapy)

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

### ● brigatinib

**Cancer type:** Non-Small Cell Lung Cancer

**Variant class:** ALK fusion

**ESMO Level of Evidence/Grade of Recommendation:** III / A

**Population segment (Line of therapy):**

- Advanced (Second-line therapy, Subsequent therapy); ESMO-MCBS v1.1 score: 3

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

### ● lorlatinib

**Cancer type:** Non-Small Cell Lung Cancer

**Variant class:** ALK fusion

**ESMO Level of Evidence/Grade of Recommendation:** III / A

**Population segment (Line of therapy):**

- Stage IV; Advanced, Progression (Second-line therapy, Subsequent therapy); ESMO-MCBS v1.1 score: 3

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

## EML4-ALK fusion (continued)

### ● brigatinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

ESMO Level of Evidence/Grade of Recommendation: III / B

Population segment (Line of therapy):

- Advanced (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

### ● ceritinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

ESMO Level of Evidence/Grade of Recommendation: IV / B

Population segment (Line of therapy):

- (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Non-Small-Cell Lung Cancer [Online Guideline (15SEP2020 - <https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer>); Ann Oncol (2018) 29 (suppl 4): iv192–iv237.]

## Clinical Trials in Taiwan region:

### Clinical Trials Summary

#### EML4-ALK fusion

NCT ID	Title	Phase
NCT03596866	A Phase III Randomized Open-label Study of Brigatinib (Alunbrig) Versus Alectinib (Alecensa) in Advanced Anaplastic Lymphoma Kinase-Positive Non Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (Xalkori)	III
NCT02584933	An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib	IV
NCT05144997	Lorlatinib (PF-06463922) Continuation Protocol: An Open-Label, Single-Arm Continuation Study For Participants With ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Continuing From Pfizer Sponsored Lorlatinib Clinical Studies	IV
NCT03093116	A Phase I/II, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	I/II
NCT04094610	A Phase I/II, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations	I/II

### Alerts Informed By Public Data Sources

#### Current NCCN Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

NCCN information is current as of 2022-10-03. For the most up-to-date information, search [www.nccn.org](http://www.nccn.org).  
For NCCN International Adaptations & Translations, search [www.nccn.org/global/international\\_adaptations.aspx](http://www.nccn.org/global/international_adaptations.aspx).

#### EML4-ALK fusion

##### atezolizumab

**Cancer type:** Non-Small Cell Lung Cancer

**Variant class:** ALK fusion

##### Summary:

NCCN Guidelines® include the following supporting statement(s):

- "subsequent therapy with pembrolizumab, nivolumab, or atezolizumab is not recommended in patients with EGFR mutations or ALK rearrangements."

**Reference:** NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

## EML4-ALK fusion (continued)

### – nivolumab

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "subsequent therapy with pembrolizumab, nivolumab, or atezolizumab is not recommended in patients with EGFR mutations or ALK rearrangements."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]

### – pembrolizumab

Cancer type: Non-Small Cell Lung Cancer

Variant class: ALK fusion

**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "subsequent therapy with pembrolizumab, nivolumab, or atezolizumab is not recommended in patients with EGFR mutations or ALK rearrangements."

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]



## Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:

## References

1. Webb et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. *Expert Rev Anticancer Ther.* 2009 Mar;9(3):331-56. PMID: 19275511
2. Shaw et al. Tyrosine kinase gene rearrangements in epithelial malignancies. *Nat. Rev. Cancer.* 2013 Nov;13(11):772-87. PMID: 24132104
3. Chiarle et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. *Nat. Med.* 2005 Jun;11(6):623-9. PMID: 15895073
4. Bai et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. *Blood.* 2000 Dec 15;96(13):4319-27. PMID: 11110708
5. Hrustanovic et al. RAS signaling in ALK fusion lung cancer. *Small GTPases.* 2016;7(1):32-3. PMID: 26901483
6. Morris et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. *Science.* 1994 Mar 4;263(5151):1281-4. PMID: 8122112
7. Kwak et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N. Engl. J. Med.* 2010 Oct 28;363(18):1693-703. PMID: 20979469
8. Yu et al. Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases. *Springerplus.* 2016 Jun 27;5(1):894. doi: 10.1186/s40064-016-2607-5. eCollection 2016. PMID: 27386342
9. Dai et al. Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas. *Send to Mol Cytogenet.* 2012 Dec 3;5(1):44. doi: 10.1186/1755-8166-5-44. PMID: 23198868
10. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/202570s033lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf)
11. Choi et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N. Engl. J. Med.* 2010 Oct 28;363(18):1734-9. PMID: 20979473
12. Awad et al. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. *Clin Adv Hematol Oncol.* 2014 Jul;12(7):429-39. PMID: 25322323
13. Kim et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. *J Thorac Oncol.* 2013 Apr;8(4):415-22. PMID: 23344087
14. Katayama et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. *Sci Transl Med.* 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25. PMID: 22277784
15. Katayama. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. *Cancer Sci.* 2018 Mar;109(3):572-580. PMID: 29336091
16. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/211225s004lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf)
17. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/208434s012lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf)
18. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/208772s013lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf)
19. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/210868s004lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf)
20. Peters et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2017 Aug 31;377(9):829-838. PMID: 28586279
21. Hida et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. *Lancet.* 2017 Jul 1;390(10089):29-39. PMID: 28501140
22. NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2022]